Ruxolitinib for relapsed or hard-to-treat T/NK cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed T-cell or NK-cell lymphoma (for skin lymphoma like CTCL, stage IB or higher).
- Your lymphoma has come back or is resistant after at least one whole-body (systemic) treatment (with a few disease-specific exceptions).
- You are age 18 or older, and your day-to-day functioning is not too limited (ECOG 0–2).
- Your lymphoma is measurable, either by imaging criteria used for lymphoma or by abnormal blood/bone marrow cells that can be counted.
- You are able to pause previous cancer treatment for at least 2 weeks before starting ruxolitinib (certain symptom steroids may be allowed if tapered to a low dose).
- Your blood and organ labs are within allowed ranges (including enough white blood cells, platelets, hemoglobin, and kidney/liver function), or you meet special lab exceptions for certain related conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
This Phase 2 study tests ruxolitinib, a targeted medicine, to improve outcomes in T-cell large granular lymphocytic leukemia (T-LGLL). It is for people whose disease is causing symptoms or who have already tried other treatment, with specific blood, infection, and medication requirements.
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests nivolumab (an immune therapy) combined with ruxolitinib (a drug that targets immune signaling) for people whose classical Hodgkin lymphoma has come back or did not respond. It may help shrink the lymphoma and improve disease control after prior treatments, including checkpoint inhibitor therapy.
This early-phase trial tests whether a combination medicine (ruxolitinib plus paclitaxel) can treat diffuse large B-cell lymphoma that has come back or did not respond to prior treatment. It may help by shrinking the lymphoma and improving control of the disease.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.